Synthesis and Evaluation of N-[1-(((3,4-Diphenylthiazol-2(3H)-ylidene)amino)methyl)cyclopentyl]acetamide Derivatives for the Treatment of Diseases Belonging to MAOs

Figure 1

IC₅₀ (μM) of the selected compounds (4a, 4b, 4c, 4d, 4e, 4f, 4g, and 4i) and control drugs against MAO-A enzyme. (a) Moclobemide (6.06 μM); (b) 4a (7.06 μM); (c) 4b (6.56 μM); (d) 4c (6.78 μM); (e) 4d (10.98 μM); (f) 4e (13.08 μM); (g) 4f (12.41 μM); (h) 4g (13.45 μM); (i) 4i (7.09 μM).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)